Mereo Biopharma Group Plc ADR (MREO) concluded trading on Thursday at a closing price of $2.51, with 3.94 million shares of worth about $9.89 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -43.34% during that period and on March 06, 2025 the price saw a loss of about -0.79%. Currently the company’s common shares owned by public are about 154.73M shares, out of which, 142.29M shares are available for trading.
Stock saw a price change of 2.45% in past 5 days and over the past one month there was a price change of -20.57%. Year-to-date (YTD), MREO shares are showing a performance of -28.29% which decreased to -34.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.25 but also hit the highest price of $5.02 during that period. The average intraday trading volume for Mereo Biopharma Group Plc ADR shares is 1.21 million. The stock is currently trading -8.16% below its 20-day simple moving average (SMA20), while that difference is down -17.89% for SMA50 and it goes to -32.73% lower than SMA200.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) currently have 154.73M outstanding shares and institutions hold larger chunk of about 66.46% of that.
The stock has a current market capitalization of $388.37M and its 3Y-monthly beta is at 0.61. It has Quick Ratio of 6.10 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MREO, volatility over the week remained 7.27% while standing at 5.78% over the month.
Stock’s fiscal year EPS is expected to drop by -53.57% while it is estimated to increase by 58.14% in next year. EPS is likely to shrink at an annualized rate of 6.69% for next 5-years, compared to annual growth of 41.78% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on December 06, 2024 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by Robert W. Baird stated Mereo Biopharma Group Plc ADR (MREO) stock as an Outperform in their note to investors on June 13, 2024, suggesting a price target of $8 for the stock. On October 13, 2023, BTIG Research Resumed their recommendations, while on August 12, 2022, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $4. Stock get a Buy rating from BTIG Research on May 05, 2021.
